Meta-analysis of effect of Qishen Yiqi Dripping Pills combined with Western medicine on adverse cardiovascular events and quality of life after percutaneous coronary intervention.
10.19540/j.cnki.cjcmm.20200618.501
- Author:
Qian-Qian DAI
1
;
Zhao-Feng SHI
1
;
Jia-Yuan HU
1
;
Song-Jie HAN
1
;
Chang-Ming ZHONG
1
;
Man-Ke GUAN
1
;
Gui-Hua TIAN
1
;
Hong-Cai SHANG
1
Author Information
1. Dongzhimen Hospital,Beijing University of Chinese Medicine Beijing 100700,China.
- Publication Type:Meta-Analysis
- Keywords:
Meta-analysis;
Qishen Yiqi Dropping Pills;
coronary heart disease;
major adverse cardiovascular events;
percutaneous coronary intervention
- MeSH:
Drugs, Chinese Herbal/adverse effects*;
Humans;
Medicine;
Percutaneous Coronary Intervention/adverse effects*;
Quality of Life;
Stroke Volume;
Ventricular Function, Left
- From:
China Journal of Chinese Materia Medica
2021;46(6):1498-1510
- CountryChina
- Language:Chinese
-
Abstract:
To systemically evaluate the effect of Qishen Yiqi Dripping Pills combined with Western medicine on adverse cardiovascular events and quality of life after percutaneous coronary intervention(PCI). A total of 7 Chinese and English databases including CNKI, Wanfang, VIP, SinoMed, PubMed, Cochrane Library and Web of Science were searched by computer to collect the randomized controlled trials(RCTs) on Qishen Yiqi Dripping Pills combined with Western medicine in the treatment of patients with coronary heart disease after PCI with the retrieval time from the database establishment to April 1, 2020. Two researchers independently conducted li-terature screening, data extraction and bias risk assessment. Then, Meta-analysis was performed by using RevMan 5.3 software. A total of 31 RCTs were included, involving 3 537 patients. The results of Meta-analysis showed that in terms of major adverse cardiovascular events(MACE) after PCI, the combination of Qishen Yiqi Dripping Pills could significantly reduce the recurrence of angina pectoris, incidence of arrhythmia, heart failure and re-revascularization, and the effect was better than that of Western medicine treatment alone. However, there was no significant difference between the two groups in the improvement of non-fatal myocardial infarction, cardiac death, stent restenosis, stroke and other adverse cardiovascular events. In terms of improving left ventricular ejection fraction(LVEF), 6 min walking test(6 MWT), high-sensitivity C-reactive protein(hs-CRP) and Seattle angina pectoris scale(SAQ), the combination of Qishen Yiqi Dripping Pills and Western medicine treatment had obvious advantages over Western medicine treatment alone in increasing LVEF, 6 MWT and SAQ, and reducing the level of hs-CRP, with statistically significant differences. There were few adverse reactions in both groups, and there was no significant difference between the two groups. The main manifestations were gastrointestinal reactions, rash, gingiva and other small bleeding, and no serious adverse reactions occurred. The above reactions could disappear after drug withdrawal or symptomatic treatment. The application of Qishen Yiqi Dripping Pills combined with Western medicine in the treatment of patients after PCI could reduce the occurrence of MACE, improve the clinical efficacy, quality of life and prognosis in a safe and reliable manner. However, due to the quantity and quality limitations of included studies, more standardized, rigo-rous and high-quality clinical studies are still needed to further verify the above conclusions.
